National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of Ustekinumab (Stelara®) in the treament of moderate to severe psoriasis.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 July 2009 November 2009 Reimbursement recommended.

We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.

 Ustekinumab (Stelara®) summary